| Fecha | Trimestre | Sesión | BPA (est → real) | Ingresos (est → reales) |
|---|---|---|---|---|
| 28 oct 2026Próximo | Q3 2026 | Tras el cierre | 0,76 | 1,73 B |
31 ago 2026
An unusually high volume of out-of-the-money (OTM) put options in Edwards Lifesciences (EW) shows investors are bullish on EW stock over the next three months. Moreover, EW is below analysts' price targets.
28 ago 2026
Aristotle Capital Management, LLC, an investment management company, released its “Value Equity Fund” Q2 2026 investor letter. A copy of the letter can be downloaded here. The Fund delivered a 4.32% total return in Q2 2026, underperforming the 13.87% gain for the Russell 1000 Value Index and the 15.20% return for the S&P 500, while […]
27 ago 2026
Disclosed in a recent SEC filing on August 26, Chopra, CVP at Edwards Lifesciences (NYSE:EW), made a noteworthy transaction involving the exercise of company stock options. What Happened: The latest Form 4 filing on
21 ago 2026
Edwards Lifesciences (EW) recently held its annual Asia Pacific Patient Experience event, spotlighting patient and caregiver perspectives on structural heart disease. For investors, the gathering raises questions about how patient engagement connects to Edwards Lifesciences stock. See our latest analysis for Edwards Lifesciences. At a share price of $89.83, Edwards Lifesciences has seen a 6.24% 30 day share price return and a 4.72% 90 day share price return, while the 1 year total shareholder...
20 ago 2026
EW's TAVR and TMTT growth support its outlook, but currency pressure and intense competition remain key risks.
Edwards Lifesciences stock has delivered a 21.6% gain over the past three years, yet the valuation checks paint a less generous picture. The intrinsic value estimate from a Discounted Cash Flow (DCF) model indicates the shares are roughly fairly valued, while traditional market multiples lean expensive. Over the last three years, Edwards Lifesciences has returned 21.6%, which rewards patient holders but leaves fresh buyers needing to judge how much upside is left at today’s...
19 ago 2026
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 20 years by 7.93% on an annualized basis producing an average annual return of 17.22%. Currently, Edwards Lifesciences has a market capitalization
As structural heart disease continues to impact a growing number of people across Asia Pacific amid a rapidly ageing population, Edwards Lifesciences (Edwards) brought together patients for its annual Asia-Pacific Patient Experience event. The programme created a platform for patients, caregivers, healthcare professionals and employees to share perspectives, foster meaningful connections and deepen understanding of the patient journey.
14 ago 2026
Edwards Lifesciences pairs accelerating structural heart growth and stronger leverage with a premium valuation that leaves less room for execution setbacks.
13 ago 2026
Edwards Lifesciences (NYSE:EW) has outperformed the market over the past 15 years by 1.31% on an annualized basis producing an average annual return of 15.06%. Currently, Edwards Lifesciences has a market capitalization
Edwards' 14% three-month rally reflects broad structural-heart growth, but its premium valuation raises the bar for execution.
12 ago 2026
Though Edwards Lifesciences has underperformed the broader market over the past year, Wall Street analysts maintain a strongly optimistic outlook on the stock’s prospects.
Edwards Lifesciences' Q2 saw 13.6% YoY sales growth, but Q3 guidance implies a sequential decline attributed to tough comps, not demand. Read more on EW stock here.
4 ago 2026
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
